

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Addiese: COMMISSIONER FOR PATENTS P O Box 1450 Alexandria, Virginia 22313-1450 www.wepto.gov

10/594.829 12/19/2007 David R. Tabatadze 24028-015 NA Beattie, Ingrid A. Mintz, Levin, Cohn, Ferris, Glovsky and Popco One Financial Center Boston, MA 02111 1656	EXAMINER	
Beattie, Ingrid A. Mintz, Levin, Cohn, Ferris, Glovsky and Popeo One Financial Center Boston, MA 02111  ARTUNIT		
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo One Financial Center Boston, MA 02111 ARTUNIT	ETTER, JAMES S	
Boston, MA 02111	KETTER, JAMES S	
	ART UNIT PAPER NUMBER	
MAIL DATE 05/18/2010	DELIVERY MODE	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Application No.	Applicant(s)	Applicant(s)  TABATADZE ET AL.		
10/594,829	TABATADZE ET AL.			
Examiner	Art Unit			
James S. Ketter	1636			

066 4-4 0	1		
Office Action Summary	Examiner	Art Unit	
	James S. Ketter	1636	
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the o	correspondence a	ddress
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DX - Extensions of time may be available under the provisions of 37 CFR 1.13 after 51% (6) MONTHS from the mailing date of this communication.  If NO period for reply is specified above, the maximum statutory period to reply with the set or extended period for reply with 14 years after the mailing earned patient term adjustment, See 37 CFR 1.70(4b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tir will apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	N. nely filed the mailing date of this of D (35 U.S.C. § 133).	,
Status			
Responsive to communication(s) filed on	_ action is non-final. nce except for formal matters, pro		e merits is
Disposition of Claims			
4) \( Claim(s)\frac{1.40}{2}\) is/are pending in the application. 4a) Of the above claim(s) is/are withdraw 5) \( Claim(s) is/are allowed. 6) \( Claim(s) is/are rejected. 7) \( Claim(s) is/are objected to. 8) \( Claim(s) \frac{1.40}{2}\) are subject to restriction and/or example and the subject to restriction and s	wn from consideration.		
9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) according to the Applicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the Example.	epted or b) objected to by the drawing(s) be held in abeyance. Se ion is required if the drawing(s) is ob	e 37 CFR 1.85(a). jected to. See 37 C	
Priority under 35 U.S.C. § 119			
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of:  1. Certified copies of the priority document: 2. Certified copies of the priority document: 3. Copies of the certified copies of the prior application from the International Bureau. * See the attached detailed Office action for a list:	s have been received. s have been received in Applicati rity documents have been receive u (PCT Rule 17.2(a)).	ion No ed in this Nationa	Stage
Attachment(s)			
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (FTO/S3/02) Page Not/Middl Date  Processing Pro	4) Interview Summary Paper No(s)/Mail D. 5) Notice of Informal F	ate	

Application/Control Number: 10/594,829

Art Unit: 1636

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1-26, drawn to methods and a product wherein the oligonucleotides are all RNA.

Group II, claim(s) 27-40, drawn to methods wherein the oligonucleotides are RNA and DNA hybrids.

The groups of inventions listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The groups of claims are mutually exclusive, and thus the feature of the composition of the oligonucleotide is not a shared technical feature, and therefore it cannot be a special technical feature of the invention.

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement may be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To preserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse. Traversal must be presented at the time of election in order to be considered timely. Failure to timely traverse the requirement will result in

Application/Control Number: 10/594,829

Art Unit: 1636

the loss of right to petition under 37 CFR 1.144. If claims are added after the election, applicant must indicate which of these claims are readable on the elected invention or species.

Should applicant traverse on the ground that the inventions have unity of invention (37 CFR 1.475(a)), applicant must provide reasons in support thereof. Applicant may submit evidence or identify such evidence now of record showing the inventions to be obvious variants or clearly admit on the record that this is the case. Where such evidence or admission is provided by applicant, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to James S. Ketter whose telephone number is 571-272-0770. The examiner can normally be reached on Monday-Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christopher Low can be reached on 571-272-0951. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/594,829 Page 4

Art Unit: 1636

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

JSK 18 May 2010

/James S. Ketter/ Primary Examiner, Art Unit 1636